Prudential Financial Inc. Trims Position in Voyager Therapeutics Inc (NASDAQ:VYGR)

Prudential Financial Inc. lessened its holdings in shares of Voyager Therapeutics Inc (NASDAQ:VYGR) by 5.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 62,670 shares of the company’s stock after selling 3,630 shares during the quarter. Prudential Financial Inc. owned approximately 0.17% of Voyager Therapeutics worth $1,706,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. Clearbridge Investments LLC lifted its stake in shares of Voyager Therapeutics by 93,030.6% during the 1st quarter. Clearbridge Investments LLC now owns 379,973 shares of the company’s stock worth $7,273,000 after purchasing an additional 379,565 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Voyager Therapeutics by 28.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 326,643 shares of the company’s stock worth $8,590,000 after purchasing an additional 71,451 shares during the period. Raymond James Financial Services Advisors Inc. lifted its stake in shares of Voyager Therapeutics by 10.6% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 202,682 shares of the company’s stock worth $3,879,000 after purchasing an additional 19,481 shares during the period. Allianz Asset Management GmbH lifted its stake in shares of Voyager Therapeutics by 16.5% during the 2nd quarter. Allianz Asset Management GmbH now owns 93,948 shares of the company’s stock worth $2,054,000 after purchasing an additional 13,339 shares during the period. Finally, Acadian Asset Management LLC lifted its stake in shares of Voyager Therapeutics by 51.8% during the 2nd quarter. Acadian Asset Management LLC now owns 70,605 shares of the company’s stock worth $1,922,000 after purchasing an additional 24,105 shares during the period. 78.49% of the stock is currently owned by institutional investors.

Several research analysts recently weighed in on VYGR shares. Wedbush increased their target price on Voyager Therapeutics from $27.00 to $36.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 18th. HC Wainwright reaffirmed a “buy” rating and issued a $26.00 target price on shares of Voyager Therapeutics in a research report on Monday, August 12th. Morgan Stanley increased their target price on Voyager Therapeutics from $21.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, July 12th. BidaskClub lowered Voyager Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 27th. Finally, ValuEngine lowered Voyager Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 4th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $27.50.

Shares of VYGR traded up $0.14 during trading hours on Thursday, hitting $18.25. The stock had a trading volume of 6,845 shares, compared to its average volume of 350,865. The firm has a market cap of $668.80 million, a P/E ratio of -6.65 and a beta of 2.63. The company’s fifty day simple moving average is $19.34 and its 200 day simple moving average is $21.65. Voyager Therapeutics Inc has a 12-month low of $7.76 and a 12-month high of $28.79.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Friday, August 9th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of ($0.88) by $1.17. The business had revenue of $46.09 million for the quarter, compared to analyst estimates of $5.25 million. Voyager Therapeutics had a negative return on equity of 71.08% and a negative net margin of 106.23%. As a group, sell-side analysts expect that Voyager Therapeutics Inc will post -2.31 EPS for the current year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.

Read More: How is a management fee different from a performance fee?

Want to see what other hedge funds are holding VYGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Voyager Therapeutics Inc (NASDAQ:VYGR).

Institutional Ownership by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.